BTK- and Venetoclax-Based Approaches Move the Needle Forward in CLL Management
April 5th 2022Inhye Ahn, MD, discusses the evolving treatment landscape of chronic lymphocytic leukemia, the advances made with BTK inhibitors and venetoclax-based regimens, novel combination regimens under exploration, and other research efforts that are underway.
Read More
Adding Uproleselan to Chemo Could Reduce Chemotherapy-Induced Mucositis in Relapsed/Refractory AML
March 30th 2022Daniel J. DeAngelo, MD, PhD, discusses how the addition of uproleselan to various chemotherapy backbones is being investigated in ongoing clinical trials, plus the encouraging safety data tied to the lowered mucositis levels.
Read More
Geriatric Assessment May Aid Treatment Decisions for Difficult-to-Treat Multiple Myeloma
March 24th 2022Alessandra Larocca, MD, PhD, discusses the use of patient- and disease-related factors that affect treatment decisions for elderly and frail patients with relapsed/refractory multiple myeloma.
Read More
Relatlimab/Nivolumab Combo Represents ‘Paradigm-Changing’ Advance in Metastatic Melanoma
March 24th 2022Hussein A. Tawbi, MD, PhD, discusses the recent FDA approval of relatlimab/nivolumab in metastatic melanoma, the significance of the regulatory decision, and potential avenues for further exploration of the regimen.
Read More
Updated KEYNOTE-564 Data Continue to Underscore Benefit of Adjuvant Pembrolizumab in RCC
March 22nd 2022Toni K. Choueiri, MD, discusses follow-up data from the pivotal phase 3 KEYNOTE-564 examining adjuvant pembrolizumab in patients with clear cell RCC and additional areas that are ripe for further research.
Read More
Axel S. Merseburger, MD, discusses the safety and efficacy results from the phase 3b PRESIDE trial examining continued enzalutamide treatment with docetaxel in select patients with metastatic castration-resistant prostate cancer who had progressed on enzalutamide monotherapy and the significance of the data for the treatment paradigm.
Read More
Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer
March 22nd 2022Nab-paclitaxel plus pembrolizumab produced an encouraging overall response rate with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or cisplatin ineligible, according to data from the phase 2 ABLE trial.
Read More
Regorafenib/Pembrolizumab Misses PFS End Point in MSS CRC, But Biomarker Analyses Are Ongoing
March 21st 2022Afsaneh Barzi, MD, PhD, discusses the safety and efficacy of regorafenib in combination with pembrolizumab in patients with MSS colorectal cancer and describes potential next steps for further exploration of novel combinations in this population.
Read More
Frederick Locke, MD, discusses the phase 3 ZUMA-7 trial examining axicabtagene ciloleucel in the second-line treatment of patients with relapsed/refractory large B-cell lymphoma, safety and efficacy findings with the therapy, and the significance of the data that have been reported to date.
Read More
Addressing Inequities in Cancer Care Starts With Awareness
March 21st 2022Alexander B. Olawaiye, MD, discusses how social and biological determinants can affect care outcomes across cancer subtypes and what steps community and academic oncologists can take to ensure these disparities are recognized.
Read More
Uproleselan Plus Chemotherapy Continues to Show Promise in AML
March 17th 2022The addition of uproleselan to standard chemotherapy improved improve response rates and reduced chemotherapy-induced mucositis in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia in a phase 1/2 trial.
Read More
Evolving Technology Behind ADCs Could Improve Benefit in Advanced Ovarian Cancer
March 11th 2022Michael Birrer, MD, PhD, discusses how new technology has transformed ADCs, how upifitamab rilsodotin could have a role in treating patients with ovarian cancer, and why the NaPi2B biomarker could be a vital target.
Read More
Phase 1/2 FELIX Trial to Determine Obe-Cel Potential in Adult Patients With ALL
March 10th 2022Claire Roddie, MD, PhD, discusses how the phase 1/2 FELIX trial could impact the treatment landscape for acute lymphoblastic leukemia, how CAR T-cell therapies have evolved, and what challenges remain in making these treatments more accessible for patients.
Read More
Eleni Efstathiou, MD, PhD, discussed the combination of niraparib and abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations, results from the MAGNITUDE trial, and next steps for research.
Read More
Bispecific Antibodies Show Potential After Relapse on CAR T-cell Therapy in Myeloma
March 2nd 2022Oliver Van Oekelen, MD, MSc, discusses findings from a retrospective study that evaluated treatment and efficacy outcomes in patients with relapsed or refractory multiple myeloma who experienced disease progression after BCMA-directed CAR T-cell therapy.
Read More
Proactive Care Is Required to Manage Belantamab Mafodotin–Associated Keratopathy in Myeloma
March 1st 2022Sarah Sunshine, MD, discusses the management of keratopathy associated with belantamab mafodotin treatment in patients with multiple myeloma and explained why ophthalmologists play a vital role in addressing these adverse effects.
Read More
ECOG-ACRIN Works to Improve Representation of Minority Populations in Cancer Clinical Trials
February 28th 2022One of the primary goals of the ECOG-ACRIN Health Equity Committee is to continue addressing disparities that limit the representation of minority populations in cancer clinical trials.
Read More
A clinical algorithm-based approach that was developed to improve fractional polynomial model selection utilized additional criteria based on face validity, predictive accuracy, and expert opinion, which improved the plausibility of survival outcomes in patients with renal cell carcinoma.
Read More
Axitinib/Pembrolizumab Shows Real-World Efficacy in Frontline Advanced RCC
February 27th 2022A real-world analysis showed that patients with advanced renal cell carcinoma in the United States who received the combination of axitinib and pembrolizumab derived similar efficacy with the regimen as those who had received it in randomized clinical trials.
Read More
MRD-Guided Treatment Approach Generates Excitement in Stage II to III Colon Cancer
February 22nd 2022The utilization of a circulating tumor DNA assay to detect the presence of minimal residual disease may provide an opportunity to better inform treatment decisions in patients with early-stage colon cancer.
Read More
Heinz-Josef Lenz, MD, discusses the safety and efficacy of nivolumab plus standard of care in patients with metastatic colorectal cancer, shares additional insight from the CheckMate-9X8 trial, and alludes to next steps with further exploring the regimen in specific subsets who appear to derive benefit from this approach.
Read More
Cabozantinib/Atezolizumab Combo Demonstrates Promising Clinical Activity in mCRC
February 18th 2022Thomas A. Abrams, MD, discusses the ongoing phase 1b COSMIC-021 trial examining cabozantinib/atezolizumab, the efficacy and safety demonstrated with the regimen in those with colorectal cancer, and the next steps for research
Read More
Pelabresib Monotherapy Shows Benefit in JAK Inhibitor–Naïve Advanced Myelofibrosis
February 17th 2022Marina Kremyanskaya, MD, PhD, discusses the safety and efficacy of pelabresib in patients with myelofibrosis, additional data from the MANIFEST trial, and other efforts investigating the agent in this disease.
Read More
Eroglu Examines the Clinical Utility of ctDNA as an Emerging Biomarker for Melanoma Treatment
February 16th 2022Zeynep Eroglu, MD, discusses the potential of ctDNA as a noninvasive biomarker in melanoma, outlines different assays under development, and details potential opportunities to leverage ctDNA in treatment decision making.
Read More